Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. 1987

R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold

Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985. Two hundred and eighty-six patients were eligible for the study of whom 145 received active drug and 141 received placebo. At the present time significantly fewer patients have relapsed or died without previous relapse in the treatment arm (P = 0.002); 43 of 145 (30%) patients receiving aminoglutethimide have relapsed or died compared with 63 of 141 (40%) of those receiving placebo. Local recurrence is also significantly reduced (P = 0.002) since only 6 patients receiving active treatment developed local recurrence compared to 21 receiving placebo. Side effects were severe enough to necessitate complete withdrawal or reduction of therapy in 27 of 145 (19%) in the treatment arm of the study compared with 21 of 141 (15%) in the placebo arm. A single treatment-related death occurred, due to agranulocytosis. Aminoglutethimide and hydrocortisone therefore delay relapse after surgery for primary breast cancer in postmenopausal women. It is too early to assess any effect on overall survival.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
January 2007, Ugeskrift for laeger,
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
December 2005, Breast (Edinburgh, Scotland),
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
January 2010, Breast care (Basel, Switzerland),
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
April 1991, Geburtshilfe und Frauenheilkunde,
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
February 2006, Clinical cancer research : an official journal of the American Association for Cancer Research,
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
April 2010, Breast (Edinburgh, Scotland),
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
January 2005, CA: a cancer journal for clinicians,
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
June 1981, Clinical oncology,
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
January 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
R C Coombes, and T J Powles, and D Easton, and C Chilvers, and H T Ford, and I E Smith, and A McKinna, and H White, and J Bradbeer, and J Yarnold
March 2018, Current treatment options in oncology,
Copied contents to your clipboard!